Novartis’ Kymriah (tisagenlecleucel) has received routine reimbursement for all eligible UK patients on the NHS, following appraisal from the Scottish Medicines Consortium. The SMC approved the CAR-T therapy for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who have not responded to two or more prior treatments. Source: PMLive 10/9/2019